Global Insulin Biosimilars Market

Insulin Biosimilars Market Size, Share, Growth Analysis, By Type(Fast-acting Insulin, Intermediate-acting Insulin), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies), By Indication(Diabetes Type 1, and Diabetes Type 2) - Industry Forecast 2024-2031

Report ID: SQMIG35B2206 | Region: Global | Published Date: May, 2024
Pages: 219 | Tables: 90 | Figures: 76

To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
$5,300
BUY NOW
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Insulin Biosimilars Market size was valued at USD 2.67 billion in 2022 and is poised to grow from USD 2.80 billion in 2023 to USD 4.07 billion by 2031, growing at a CAGR of 4.8% in the forecast period (2024-2031).

Insulin biosimilars market players can capitalize on the increasing incidence of diabetes by marketing their products as the right choice for effective diabetes management. Insulin biosimilar companies should also utilize strategies such as collaborations, partnerships, and mergers to fast-track the development of new insulin biosimilars. Companies can also improve their commercialization times by leveraging lucrative regulatory norms. 'Eli Lilly and Company', 'BIOTON S.A.', 'Merck & Co.', 'WOCKHARDT', 'Sanofi SA', 'Fresenius Kabi', 'Mylan N.V.', 'Julphar', 'Biocon Ltd.', 'Tonghua Dongbao', 'SEDICO Co.', 'Boehringer Ingelheim', 'Advanced Chemical Industries Limited', 'Aristopharma Ltd.', 'Amgen', 'Novo Nordisk A/S', 'Polfa Tarchomin S.A.', 'Sandoz', 'Popular Pharmaceuticals Ltd.', 'Denver Farma S.A'

Originator insulin products and biosimilars that have been used for years are now facing patent expiration issues and this is projected to bolster the demand for novel and innovative new insulin biosimilars. High investments in medical R&D are projected to create new opportunities for insulin biosimilar providers.

Adoption of Biologic and Biosimilar Therapies for Diabetes: Patients as well as healthcare institutions are focusing on adoption of novel biosimilar and biologic therapies for diabetes management, and this is slated to create new opportunities for suppliers of insulin biosimilars. Companies can develop novel products that are in accordance with this trend to maximize their revenue generation going forward.

North America is slated to hold sway over global insulin biosimilars demand outlook across the forecast period. High prevalence of diabetic demographic in this region is the key factor supporting its dominance. Poor eating habits and adoption of sedentary lifestyles are key factors that have given rise to incidence of diabetes in North American countries. High healthcare spending potential and the presence of key pharmaceutical companies will also bolster the demand for insulin biosimilars in this region with United States accounting for the largest market share and Canada the second largest in North America.

Related Reports

Biosimilars Market
Buy Now GET FREE SAMPLE
Human Insulin Market
Buy Now GET FREE SAMPLE
Insulin Storage Devices Market
Buy Now GET FREE SAMPLE
Insulin Pump Market
Buy Now GET FREE SAMPLE
Diabetes Device Market
Buy Now GET FREE SAMPLE
Insulin Pens Market
Buy Now GET FREE SAMPLE
Diabetes Care Devices and Drugs Market
Buy Now GET FREE SAMPLE
Smart Insulin Pens Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Insulin Biosimilars Market

Product ID: SQMIG35B2206

$5,300
BUY NOW